ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.

Positive

• PIPE financing of $60.0M closed in October 2025
• Estimated net PIPE proceeds of $57.6M
• Pro forma cash position of ~$292.3M after PIPE
• Phase 2 FL IIT: ORR 98.2% and CR 83.6% (12‑month PFS 93.9%)
• LOTIS-5 topline expected in 1H 2026

Negative

• Q3 product revenue declined to $15.8M from prior-year quarter
• Nine-month net loss widened to $136.2M
• R&D nine-months increased to $85.8M driven by IND work
• Restructuring and impairments of $13.5M year-to-date

Insights

Senior Biopharma Analyst

Positive operational update: meaningful financing, strong IIT efficacy signals, and clear near‑term clinical catalysts with extended cash runway.

The company strengthened its liquidity via a $60 million PIPE (net ~$57.6 million), implying pro‑forma cash of ~$292.3 million, which the company says will fund commercial expansion of ZYNLONTA. Clinical progress includes expanded and durable efficacy signals in the Phase 2 IIT for relapsed/refractory follicular lymphoma (ORR 98.2%, CR 83.6%, 12‑month PFS 93.9% with median follow‑up 28 months) and scheduled readouts: updated LOTIS‑7 data by end of year and LOTIS‑5 topline in 1H 2026. These are concrete, monitorable catalysts tied to regulatory engagement and potential sBLA activity.

Key dependencies and risks remain: commercial scale‑up success hinges on adoption in 2L+ DLBCL and indolent lymphoma, and regulatory steps require confirmatory positive results before approval filings. Revenue trends show modest period‑over‑period declines (quarterly net product revenues of $15.8 million vs $18.0 million prior year), and R&D plus restructuring drove a nine‑month net loss of $136.2 million. Watch upcoming readouts (LOTIS‑7 by end of year; LOTIS‑5 topline in 1H 2026) and any FDA engagement timelines through 1H 2027 for publication/compendia plans.

Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026

Updated data from Phase 2 IIT of ZYNLONTA^®  plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma

Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028

LAUSANNE, Switzerland, Nov. 10, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates.

"The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA^® as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "We look forward to multiple upcoming clinical catalysts expected across LOTIS-7, LOTIS-5, and the ongoing Phase 2 IITs, starting with LOTIS-7 before the end of this year and continuing with data readouts throughout 2026."

Third Quarter 2025 Operational Updates & Recent Highlights

• Completed private investment in public equity (PIPE) financing. The Company entered into a securities purchase agreement for the sale of its equity securities to certain institutional investors in a $60 million PIPE financing, of which the net proceeds of approximately $57.6 million are anticipated to fund the commercial expansion of ZYNLONTA and strengthen the Company's balance sheet.
• Updated data from LOTIS-7 expected by the end of the year. Beyond the initial results reported at European Hematology Association 2025 Congress (EHA2025) and at the International Conference on Malignant Lymphoma (ICML) in June from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), the Company expects to share additional data from the LOTIS-7 trial through a corporate update by the end of the year. Once sufficient data with longer follow-up is available, the Company plans to engage with the U.S. Food and Drug Administration (FDA). In addition, the Company plans to pursue publication and compendia inclusion in the first half of 2027.
• LOTIS-5 topline results anticipated in 1H 2026. The Company expects to provide topline data in the first half of 2026 from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL once the pre-specified number of progression-free survival (PFS) events is reached and data are available. Assuming positive results, a supplemental Biologics License Application (sBLA) submission to regulatory authorities will follow, with potential confirmatory approval in 2L+ DLBCL as well as publication and compendia inclusion in the first half of 2027.
• Updated data from the Phase 2 investigator-initiated trial (IIT) of ZYNLONTA in r/r follicular lymphoma (FL) presented at the 22^nd International Workshop on Non-Hodgkin Lymphoma (iwNHL). Juan Pablo Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presented updated data at iwNHL in September from the Phase 2 IIT evaluating ZYNLONTA in combination with rituximab in r/r FL. Data from the 55 efficacy-evaluable patients to date in this trial continue to demonstrate encouraging results with an overall response rate (ORR) of 98.2%, a complete response rate (CR) of 83.6%. After median follow-up of 28 months, median PFS was not reached, and the 12-month PFS was 93.9%. Safety was consistent with the known profile of ZYNLONTA. The trial has been expanded to enroll 100 patients, and the Company plans to assess regulatory and updated compendia pathways as soon as sufficient data are available.
• IND-enabling activities advancing for PSMA-targeting ADC. IND-enabling activities are ongoing for the Company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC with completion of these activities expected by the end of 2025.

Third Quarter and Year-to-Date 2025 Financial Results

• Product Revenues: Net product revenues were $15.8 million for the three months ended September 30, 2025, and $51.2 million for the nine months of 2025 as compared to $18.0 million and $52.9 million for the same periods in 2024. The period-over-period changes were primarily driven by lower sales volume, partially offset by higher sales price and favorability in gross-to-net sales adjustments.
• Research and Development (R&D) Expense: R&D expense was $26.8 million for the three months ended September 30, 2025, as compared to $32.5 million for the same period in 2024. The decrease in R&D costs for the three-month period was driven by a reduction in spending on discontinued programs and timing and enrollment of our ZYNLONTA clinical trials, partially offset by an increase in IND-enabling activities for our PSMA-targeting ADC. R&D expense was $85.8 million for the nine months ended September 30, 2025, as compared to $82.5 million for the same period in 2024. The increase in R&D costs for the nine-month period was driven by an increase in IND-enabling activities for our PSMA-targeting ADC and timing and enrollment of our ZYNLONTA clinical trials, partially offset by a reduction in spending on discontinued programs.
• Selling and Marketing (S&M) Expense: S&M expenses were relatively consistent at $10.7 million for the three months ended September 30, 2024, and 2025, respectively. S&M expense was $31.4 million for the nine months ended September 30, 2025, as compared to $32.8 million for the same period in 2024. The period-over-period decrease was primarily due to a reduction in marketing and advertising expenses.
• General & Administrative (G&A) Expense: G&A expense was $8.3 million and $27.1 million for the three and nine months ended September 30, 2025, respectively, compared to $10.0 million and $32.3 million for the same periods in 2024. The reductions in G&A expense were primarily due to lower external professional fees.
• Restructuring, impairment and other related costs: In connection with the strategic reprioritization and restructuring plan announced in June 2025, the Company incurred $0.4 million and $13.5 million in restructuring, impairment and other related costs for the three and nine months ended September 30, 2025, which consisted of $6.2 million in employee severance and related benefit costs, $6.4 million in non-cash impairment of assets and $0.8 million in retirement costs in connection with the close down of the UK facility.
• Net Loss: Net loss for the three months ended September 30, 2025, was $41.0 million, or a net loss of $0.30 per basic and diluted share, as compared to a net loss of $44.0 million, or a net loss of $0.42 per basic and diluted share, for the same period in 2024. The lower net loss for the three-month period was primarily due to lower R&D and G&A expenses. Net loss for the nine months ended September 30, 2025, was $136.2 million, or a net loss of $1.14 per basic and diluted share, as compared to a net loss of $127.1 million, or a net loss of $1.35 per basic and diluted share, for the same period in 2024. The higher net loss for the nine-month period was primarily due to the increase in R&D expense, the restructuring, impairment and related costs incurred in connection with the strategic reprioritization and restructuring plan and lower interest income.
• Adjusted Net Loss: Adjusted net loss, which is a non-GAAP financial measure, was $25.5 million, or an adjusted net loss of $0.19 per basic and diluted share for the three months ended September 30, 2025, as compared to adjusted net loss of $29.4 million, or $0.28 per basic and diluted share, for the same period in 2024. Adjusted net loss for the nine months ended September 30, 2025, was $78.2 million, or an adjusted net loss of $0.66 per basic and diluted share, as compared to an adjusted net loss of $84.9 million, or $0.90 per basic and diluted share, for the same period in 2024. The decrease in adjusted net loss for the three-month and nine-month periods was due to lower operating expenses and a higher number of weighted average shares outstanding.
• Cash and cash equivalents: As of September 30, 2025, cash and cash equivalents were $234.7 million, compared to $250.9 million as of December 31, 2024. In October, the Company entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million PIPE financing. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6 million (after deducting placement agent fees and estimated offering expenses), the Company would have had approximately $292.3 million of cash and cash equivalents as of that date.

Conference Call Details

ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2025 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events & Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC.

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Use of Non-GAAP Financial Measures

In addition to financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), this document also contains certain non-GAAP financial measures based on management's view of performance including:

• Adjusted total operating expenses
• Adjusted net loss
• Adjusted net loss per share

Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-GAAP measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with GAAP. When preparing these supplemental non-GAAP measures, management typically excludes certain GAAP items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these GAAP items to be normal, recurring cash operating expenses; however, these items may not meet the GAAP definition of unusual or non-recurring items. Since non-GAAP financial measures do not have standardized definitions and meanings, they may differ from the non-GAAP financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other GAAP financial measures.

The following items are excluded from adjusted total operating expenses:

Shared-Based Compensation Expense: We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

Restructuring, Impairment and Other Related Costs: We exclude from our adjusted financial measures costs associated with our execution of certain strategies and initiatives to streamline operations, achieve targeted cost reductions or reprioritize research and development activities. These costs may include employee severance, contract termination costs, facility closing and exit costs, asset impairment charges (which are non-cash) and other costs that we believe do not represent the performance of our business or have a direct correlation to our ongoing or future business operations.

The following items are excluded from adjusted net loss and adjusted net loss per share:

Shared-Based Compensation Expense: We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

Certain Other Items: We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be: restructuring, impairment and other related costs, changes in the fair value of warrant obligations and the effective interest expense associated with the senior secured term loan facility and the effective interest expense and cumulative catch-up adjustments associated with the deferred royalty obligation under the royalty purchase agreement with HealthCare Royalty Partners.

See the attached Reconciliation of GAAP Measures to Non-GAAP Measures for explanations of the amounts excluded and included to arrive at the non-GAAP financial measures.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated proceeds to be received in the PIPE, the Company's expected use of proceeds, the expected timing of the closing of the PIPE, the Company's long-term growth potential, the Company's strengthened balance sheet and expected cash runway into 2028, and the Company's expected net product revenues from sales of ZYNLONTA for the third quarter ended September 30, 2025 and its cash and cash equivalents as of September 30, 2025. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the strengthened balance sheet and expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions and trade barriers and potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

 

ADC Therapeutics SA Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share data)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2025		2024		2025		2024
Revenue
Product revenues, net		$            15,750		$            18,016		$         51,239		$         52,894
License revenues and royalties		677		448		7,060		1,033
Total revenue, net		16,427		18,464		58,299		53,927
Operating expense
Cost of product sales		(1,202)		(851)		(4,099)		(4,578)
Research and development		(26,803)		(32,502)		(85,821)		(82,532)
Selling and marketing		(10,688)		(10,673)		(31,388)		(32,764)
General and administrative		(8,326)		(10,002)		(27,103)		(32,271)
Restructuring, impairment and other related costs		(377)		—		(13,468)		—
Total operating expense		(47,396)		(54,028)		(161,879)		(152,145)
Loss from operations		(30,969)		(35,564)		(103,580)		(98,218)
Other income (expense)
Interest income		2,470		3,438		6,458		9,639
Interest expense		(13,392)		(13,117)		(38,619)		(38,292)
Other, net		925		1,624		946		1,783
Total other expense, net		(9,997)		(8,055)		(31,215)		(26,870)
Loss before income taxes		(40,966)		(43,619)		(134,795)		(125,088)
Income tax expense		—		(90)		(1,419)		(487)
Loss before equity in net losses of joint venture		(40,966)		(43,709)		(136,214)		(125,575)
Equity in net losses of joint venture		—		(260)		—		(1,544)
Net loss		$          (40,966)		$          (43,969)		$     (136,214)		$     (127,119)
Net loss per share
Net loss per share, basic and diluted		$               (0.30)		$              (0.42)		$            (1.14)		$           (1.35)
Weighted average shares outstanding, basic and diluted		136,446,534		104,824,877		119,237,877		94,394,355

 

ADC Therapeutics SA Condensed Consolidated Balance Sheets (Unaudited) (in thousands)
		September 30, 2025		December 31, 2024
ASSETS
Current assets
Cash and cash equivalents		$               234,738		$               250,867
Accounts receivable, net		22,918		20,316
Inventory		18,042		18,387
Prepaid expenses		5,928		8,370
Other current assets		5,523		9,450
Total current assets		287,149		307,390
Non-current assets
Property and equipment, net		—		5,075
Operating lease right-of-use assets		1,393		8,354
Other long-term assets		1,216		1,161
Total assets		$               289,758		$               321,980
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Current liabilities
Accounts payable		$                   8,119		$                 18,029
Accrued expenses and other current liabilities		53,925		62,440
Total current liabilities		62,044		80,469
Deferred royalty obligation, long-term		340,170		320,093
Senior secured term loans		115,206		113,632
Operating lease liabilities, long-term		1,127		7,995
Other long-term liabilities		9,394		2,433
Total liabilities		527,941		524,622
Total shareholders' (deficit) equity		(238,183)		(202,642)
Total liabilities and shareholders' (deficit) equity		$               289,758		$               321,980

 

ADC Therapeutics SA Reconciliation of GAAP Measures to Non-GAAP Measures (Unaudited) (in thousands, except for share and per share data)
	Three Months Ended September 30,									Nine Months Ended September 30,
(in thousands)	2025		2024		Change			% Change		2025				2024				Change				% Change
Total operating expense	$   (47,396)		$   (54,028)		$   6,632			(12) %		$   (161,879)				$   (152,145)				$   (9,734)				6 %
Adjustments:
Share-based compensation expense (i)	1,999		2,806		(807)			(29) %		6,482				4,952				1,530				31 %
Restructuring charges (v)	377		—		377			N/A		7,054				—				7,054				N/A
Impairment charges (vi)	—		—		—			N/A		6,414				—				6,414				N/A
Adjusted total operating expenses	$   (45,020)		$   (51,222)		$   6,202			(12) %		$   (141,929)				$   (147,193)				$     5,264				(4) %
						Three Months Ended September 30,										Nine Months Ended September 30,
in thousands (except for share and per share data)						2025						2024				2025				2024
Net loss						$      (40,966)						$      (43,969)				$   (136,214)				$    (127,119)
Adjustments:
Share-based compensation expense (i)						1,999						2,806				6,482				4,952
Deerfield warrants obligation, change in fair value (income)/expense (ii)						—						(1,130)				—				(292)
Effective interest expense on senior secured term loan facility (iii)						4,396						4,585				12,455				13,401
Deferred royalty obligation interest expense (iv)						8,996						8,532				26,164				24,891
Deferred royalty obligation cumulative catch-up adjustment income (iv)						(321)						(206)				(517)				(732)
Restructuring charges (v)						377						—				7,054				—
Impairment charges (vi)						—						—				6,414				—
Adjusted net loss						$      (25,519)						$      (29,382)				$      (78,162)				$      (84,899)
Net loss per share, basic and diluted						$          (0.30)						$          (0.42)				$          (1.14)				$          (1.35)
Adjustment to net loss per share, basic and diluted						0.11						0.14				0.48				0.45
Adjusted net loss per share, basic and diluted						$          (0.19)						$          (0.28)				$          (0.66)				$          (0.90)
Weighted average shares outstanding, basic and diluted						136,446,534						104,824,877				119,237,877				94,394,355

(i)	Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted and is recognized over the requisite service period less actual forfeitures by a charge to the statement of operations and a corresponding increase in additional paid-in capital within equity. These accounting entries have no cash impact.
(ii)	Change in the fair value of the Deerfield warrant obligation results from the valuation at the end of each accounting period. There are several inputs to these valuations, but those most likely to result in significant changes to the valuations are changes in the value of the underlying instrument (i.e., changes in the price of our common shares) and changes in expected volatility in that price. These accounting entries have no cash impact.
(iii)	Effective interest expense on senior secured term loans relates to the increase in the value of our loans in accordance with the amortized cost method.
(iv)	Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustments related to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections.
(v)	Restructuring charges consist primarily of employee severance, contract termination costs and other costs associated to the strategic reprioritization and restructuring plan approved by the Board of Directors on June 11, 2025 ("2025 Restructuring").
(vi)	Impairment charges consist of write downs of long-lived and prepaid assets associated with the 2025 Restructuring. These accounting entries have no cash impact.

 

CONTACT:
Investors & Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-reports-third-quarter-2025-financial-results-and-provides-operational-update-302608959.html

SOURCE ADC Therapeutics SA

FAQ

What did ADC Therapeutics announce on Nov 10, 2025 for ADCT?

ADC reported Q3 2025 results, a $60M PIPE, and clinical updates including LOTIS-7 and LOTIS-5 timelines.

How much cash would ADCT have after the October 2025 PIPE financing?

Including estimated net proceeds of $57.6M, ADCT would have approximately $292.3M in cash.

When will ADCT report LOTIS-7 and LOTIS-5 data for ZYNLONTA?

LOTIS-7 updated data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026.

What were ADCT’s Q3 2025 revenue and net loss (ADCT)?

Q3 product revenue was $15.8M; Q3 net loss was $41.0M or $0.30 per share.

What efficacy did the Phase 2 FL investigator-initiated trial report for ZYNLONTA?

The trial reported an overall response rate of 98.2%, complete response 83.6%, and 12‑month PFS 93.9%.

What is the status of ADCT’s PSMA-targeting ADC IND-enabling activities?

IND-enabling activities are ongoing with completion expected by the end of 2025.